Tétu P - Search Results

1

Mitogen-activated protein kinase blockade in melanoma: intermittent versus continuous therapy, from preclinical to clinical data.

Tétu P, Vercellino L, Reger de Moura C, Baroudjian B, Dumaz N, Mourah S, Lebbé C. Tétu P, et al. Curr Opin Oncol. 2021 Mar 1;33(2):127-132. doi: 10.1097/CCO.0000000000000706. Curr Opin Oncol. 2021. PMID: 33315631 Review.

2

Targeting BRAF and MEK inhibitors in melanoma in the metastatic, neoadjuvant and adjuvant setting.

Tétu P, Baroudjian B, Lebbe C. Tétu P, et al. Curr Opin Oncol. 2020 Mar;32(2):85-90. doi: 10.1097/CCO.0000000000000614. Curr Opin Oncol. 2020. PMID: 31895121 Review.

3

FGF2 Induces Resistance to Nilotinib through MAPK Pathway Activation in KIT Mutated Melanoma.

Tétu P, Delyon J, André J, Reger de Moura C, Sabbah M, Ghanem GE, Battistella M, Mourah S, Lebbé C, Dumaz N. Tétu P, et al. Cancers (Basel). 2020 Apr 25;12(5):1062. doi: 10.3390/cancers12051062. Cancers (Basel). 2020. PMID: 32344828 Free PMC article.

4

A Melanoma-Tailored Next-Generation Sequencing Panel Coupled with a Comprehensive Analysis to Improve Routine Melanoma Genotyping.

Louveau B, Jouenne F, Têtu P, Sadoux A, Gruber A, Lopes E, Delyon J, Serror K, Marco O, Da Meda L, Ndiaye A, Lermine A, Dumaz N, Battistella M, Baroudjian B, Lebbe C, Mourah S. Louveau B, et al. Among authors: tetu p. Target Oncol. 2020 Dec;15(6):759-771. doi: 10.1007/s11523-020-00764-4. Target Oncol. 2020. PMID: 33151472

5

["Biomedicines in oncodermatology"].

Gauci ML, Baroudjian B, Herms F, Tetu P, Jebali M, Nicole N, Lebbé C. Gauci ML, et al. Among authors: tetu p. Rev Prat. 2021 Feb;71(2):123-132. Rev Prat. 2021. PMID: 34160967 French. No abstract available.

6

Which adjuvant treatment for patients with BRAF^V600-mutant cutaneous melanoma?

Funck-Brentano E, Malissen N, Roger A, Lebbé C, Deilhes F, Frénard C, Dréno B, Meyer N, Grob JJ, Tétu P, Saiag P. Funck-Brentano E, et al. Among authors: tetu p. Ann Dermatol Venereol. 2021 Sep;148(3):145-155. doi: 10.1016/j.annder.2020.11.006. Epub 2021 Feb 9. Ann Dermatol Venereol. 2021. PMID: 33579557 Free article. Review.

7

[Update in treatment for Merkel Cell Carcinoma and clinical practice guide].

Tétu P, Baroudjian B, Madelaine I, Delyon J, Lebbé C. Tétu P, et al. Bull Cancer. 2019 Jan;106(1):64-72. doi: 10.1016/j.bulcan.2018.11.009. Epub 2018 Dec 19. Bull Cancer. 2019. PMID: 30579571 Review. French.

8

Reintroduction of immune-checkpoint inhibitors after immune-related meningitis: a case series of melanoma patients.

Cuzzubbo S, Tetu P, Guegan S, Ursu R, Belin C, Sirven Villaros L, Mazoyer J, Lheure C, Lebbe C, Baroudjian B, Carpentier AF. Cuzzubbo S, et al. Among authors: tetu p. J Immunother Cancer. 2020 Jul;8(2):e001034. doi: 10.1136/jitc-2020-001034. J Immunother Cancer. 2020. PMID: 32747471 Free PMC article.

9

Impact of New Systemic Treatment and Radiotherapy in Melanoma Patients with Leptomeningeal Metastases.

Tétu P, Sirven-Villaros L, Cuzzubbo S, Ursu R, Baroudjian B, Delyon J, Nataf F, De Margerie-Mellon C, Allayous C, Lefevre W, Carpentier AF, Lebbé C. Tétu P, et al. Cancers (Basel). 2020 Sep 16;12(9):2635. doi: 10.3390/cancers12092635. Cancers (Basel). 2020. PMID: 32947841 Free PMC article.

10

Increased risk of brain metastases among patients with melanoma and PROM2 expression in metastatic lymph nodes.

Nguyen TT, Gapihan G, Tetu P, Pamoukdjian F, El Bouchtaoui M, Lebœuf C, Feugeas JP, Paris J, Baroudjian B, Delyon J, Mourah S, Lebbé C, Janin A, Bousquet G, Battistella M. Nguyen TT, et al. Among authors: tetu p. Clin Transl Med. 2020 Dec;10(8):e198. doi: 10.1002/ctm2.198. Clin Transl Med. 2020. PMID: 33377645 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

22 results

Search Page